Related Experiment Videos
Plasmatic fibronectin in malignancies
P Gallurt1, P Rodriguez, A Lorenzo
1Department of Medicine, Faculty of Medicine, University of Cadiz, Spain.
The International Journal of Biological Markers
|October 1, 1992
Summary
Plasmatic fibronectin levels show potential as a cancer biomarker. While overall levels didn't differ, breast cancer patients had higher fibronectin, and head and neck cancer patients had lower levels.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Background:
- Unspecific opsonins, like fibronectin, may influence tumor progression.
- Altered fibronectin levels are being investigated as potential biological markers for cancer diagnosis.
Purpose of the Study:
- To evaluate the diagnostic significance of plasmatic fibronectin levels in cancer patients.
- To determine if fibronectin serves as a useful biomarker for specific tumor types.
Main Methods:
- Comparison of plasmatic fibronectin levels between a control group and tumor patients.
- Analysis of fibronectin levels based on tumor location.
- Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic accuracy.
Main Results:
- No significant difference in overall plasmatic fibronectin levels between control and tumor patient groups.
- Significant increase in fibronectin levels observed in breast cancer patients (31.83 +/- 3.83 mg/dl).
- Significant decrease in fibronectin levels observed in squamous cell carcinoma of the head and neck (9.56 +/- 1.68 mg/dl).
Conclusions:
- Plasmatic fibronectin may serve as a valuable biomarker for specific cancer types, such as breast cancer and head and neck cancers.
- The diagnostic utility of fibronectin as a cancer biomarker is supported by ROC curve analysis.
- Further research is warranted to elucidate the role of fibronectin in different oncological contexts.